Cargando…
ACE-I/ARB Therapy prior to Contrast Exposure: What Should the Clinician Do?
Contrast-induced nephropathy (CIN) is now one of the three leading causes of acute kidney injury in the world. A lot is known about the risk factors of CIN, yet it remains a major cause of morbidity, end stage renal disease, prolonged hospital stay, and increased costs as well as a high mortality. M...
Autores principales: | Kalyesubula, Robert, Bagasha, Peace, Perazella, Mark A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3925541/ https://www.ncbi.nlm.nih.gov/pubmed/24605330 http://dx.doi.org/10.1155/2014/423848 |
Ejemplares similares
-
What Evidence Supports Guidelines for Use of ACE Inhibitors and ARBs in Diabetes?
por: Curtiss, Frederic R.
Publicado: (2006) -
ACE2 localizes to the respiratory cilia and is not increased by ACE inhibitors or ARBs
por: Lee, Ivan T., et al.
Publicado: (2020) -
Acute kidney injury among adult patients with sepsis in a low-income country: clinical patterns and short-term outcomes
por: Bagasha, Peace, et al.
Publicado: (2015) -
Controversy regarding ACE inhibitors / ARBs in COVID-19
por: Soria Arcos, Federico, et al.
Publicado: (2020) -
ACE-inhibitor/angiotensin receptor blockers (ACE-I/ARBs) therapy in COVID-19 infected dialysis patients
por: Daoud, Ahmed, et al.
Publicado: (2021)